Scarica l'app Stockscreener
0.196
8.89%
0.016
Dopo l'orario di chiusura:
.19
-0.006
-3.06%
Precedente Chiudi:
$0.18
Aprire:
$0.189
Volume 24 ore:
1.49M
Relative Volume:
2.84
Capitalizzazione di mercato:
$3.85M
Reddito:
-
Utile/perdita netta:
$-20.26M
Rapporto P/E:
-0.023
EPS:
-8.54
Flusso di cassa netto:
$-8.25M
1 W Prestazione:
+9.31%
1M Prestazione:
+2.62%
6M Prestazione:
-42.35%
1 anno Prestazione:
-86.93%
Intervallo 1D:
$0.1801
$0.205
Intervallo di 1 settimana:
$0.1648
$0.205
Portata 52W:
$0.1617
$3.43
Oragenics Inc Stock (OGEN) Company Profile
Nome
Oragenics Inc
Settore
Industria
Telefono
813-286-7900
Indirizzo
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Confronta OGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.196 | 3.85M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Oragenics Inc Borsa (OGEN) Ultime notizie
Oragenics (OGEN) Gains Approval for Phase II Trial of Neuroprote - GuruFocus
Oragenics gains Australia’s nod for concussion therapy trial - Investing.com Australia
Oragenics gains Australia’s nod for concussion therapy trial By Investing.com - Investing.com Nigeria
Oragenics, Inc. Announces Approval to Initiate Phase II Concussi - GuruFocus
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - The Manila Times
Oragenics, Inc. to Host Management Update Webinar on May - GlobeNewswire
Oragenics, Inc. to Host Management Update Webinar on May 20, 202 - GuruFocus
Oragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion Treatment - Nasdaq
Oragenics: Q1 Earnings Snapshot - New Haven Register
Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World
Oragenics Appoints New CEO and Amends Employment Terms By Investing.com - Investing.com Nigeria
Oragenics Appoints New CEO and Amends Employment Terms - Investing.com Australia
Oragenics Appoints Janet Huffman as CEO and CFO - TipRanks
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Defense World
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brai - GuruFocus
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference | OGEN Stock News - GuruFocus
Oragenics, Inc. to Present at the 15th Annual Traumatic Brain Injury Conference on Advances in mTBI Detection and Management - Nasdaq
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference - GlobeNewswire
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Health and Disability Ethics Committee - GuruFocus
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial - The Manila Times
Oragenics Announces Health And Disability Ethics Committee Submission - MarketScreener
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - GlobeNewswire
Oragenics gears up for Phase II trials, appoints new CEO - MSN
Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com - Defense World
OGEN stock touches 52-week low at $0.19 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.19 amid sharp annual decline - Investing.com
OGEN stock touches 52-week low at $0.24 amid sharp annual decline - Investing.com Australia
Oragenics reports progress in concussion drug development By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.24 amid sharp annual decline By Investing.com - Investing.com South Africa
Oragenics reports progress in concussion drug development - Investing.com
Oragenics Provides Q1 2025 Shareholder Update On Strategic And Financial Progress - MarketScreener
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress - The Manila Times
Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
Investornewsbreaks Oragenics Inc. Files 2024 Annual Report, Addresses Going Concern Status - MENAFN.COM
Oragenics Inc Azioni (OGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):